APP and Alzheimer disease: Regardless of whether activation of ADAM10 leads to a decrease in Aβ by shifting the balance of APP processing between the nonamyloidogenic and amyloidogenic pathways, activation of ADAM10 could be beneficial in AD by acting through other mechanisms.